- Report
- October 2024
- 190 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 130 Pages
Global
From €3973EUR$4,365USD£3,406GBP
€4414EUR$4,850USD£3,784GBP
- Drug Pipelines
- November 2020
- 78 Pages
Global
From €3185EUR$3,500USD£2,731GBP
- Report
- January 2022
- 90 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Report
- November 2023
- 198 Pages
Global
From €3275EUR$3,599USD£2,808GBP
- Report
- December 2023
- 173 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- January 2024
- 84 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Book
- July 2018
- 488 Pages
The Proteasome market is a subset of the larger Enzymes market. Proteasomes are a type of enzyme that are responsible for the breakdown of proteins into smaller peptides and amino acids. They are found in all eukaryotic cells and are essential for the regulation of cell cycle, apoptosis, and other cellular processes. Proteasomes are used in a variety of research and therapeutic applications, including drug discovery, cancer research, and immunology.
The Proteasome market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Merck KGaA, Thermo Fisher Scientific, Bio-Rad Laboratories, Sigma-Aldrich, and Promega Corporation. Show Less Read more
